UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $7.11 Million Stake in LivaNova PLC (NASDAQ:LIVN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 25.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 153,458 shares of the company's stock after acquiring an additional 30,718 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.28% of LivaNova worth $7,107,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of LIVN. PNC Financial Services Group Inc. grew its stake in shares of LivaNova by 29.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after purchasing an additional 1,424 shares during the period. Rhumbline Advisers increased its stake in shares of LivaNova by 0.5% in the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after acquiring an additional 899 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of LivaNova in the 4th quarter worth $2,772,000. Envestnet Asset Management Inc. increased its position in shares of LivaNova by 15.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after purchasing an additional 5,850 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its position in shares of LivaNova by 147.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company's stock worth $4,582,000 after purchasing an additional 58,911 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LIVN. Barclays dropped their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Robert W. Baird boosted their price objective on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Mizuho cut their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group dropped their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $59.29.

LivaNova Stock Performance

LivaNova stock traded up $0.37 during mid-day trading on Thursday, hitting $44.85. 580,397 shares of the company's stock traded hands, compared to its average volume of 657,934. LivaNova PLC has a one year low of $32.48 and a one year high of $57.35. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a 50 day moving average price of $39.31 and a 200 day moving average price of $44.16. The company has a market cap of $2.45 billion, a PE ratio of 106.79 and a beta of 0.84.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.